<?xml version="1.0" encoding="UTF-8"?>
<p>China is home to nearly one third of all people living with hepatitis B infection globally. HBsAg prevalence is estimated at 5.5%
 <xref rid="liv14222-bib-0002" ref-type="ref">2</xref> and hepatitis B causes over 300 000 deaths annually due to liver diseases.
 <xref rid="liv14222-bib-0069" ref-type="ref">69</xref> The implementation of a universal hepatitis B vaccination programme for infants has reduced chronic hepatitis B incidence dramatically during the past two decades. The full implementation of a national programme for the prevention of MTCT guarantees adequate supply of HBIg for at‐risk newborns. Domestic procurement of the hepatitis B vaccine and auto‐disable syringes ensures sustainable supply chains and stimulates regional industry and technology markets.
 <xref rid="liv14222-bib-0070" ref-type="ref">70</xref>
</p>
